BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2026 7:03:49 AM | Browse: 2 | Download: 0
 |
Received |
|
2026-04-09 03:21 |
|
Peer-Review Started |
|
2026-04-09 03:23 |
|
First Decision by Editorial Office Director |
|
2026-04-16 07:57 |
|
Return for Revision |
|
2026-04-17 05:55 |
|
Revised |
|
2026-05-10 09:27 |
|
Publication Fee Transferred |
|
2026-05-12 06:32 |
|
Second Decision by Editor |
|
2026-06-02 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-06-02 07:42 |
|
Articles in Press |
|
2026-06-02 07:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-17 01:54 |
|
Publish the Manuscript Online |
|
2026-07-24 07:03 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Basic Study |
| Article Title |
Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Xuan Tao, Di-Hong Gong, Huan Yang, Peng-Quan Wang, Yan-Mei Tang, Qi-Di Zhou, Yan-Yan Wang, Yue Zhang, Wei-Dong Chen, Jie Yu and Xing-Xin Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xing-Xin Yang, College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Yunnan Key Laboratory of Southern Medicine Utilization, No. 1076 Yuhua Road, Kunming 650500, Yunnan Province, China. yxx78945@163.com |
| Key Words |
Effective substances; Fuling Zexie decoction; Lipid metabolism; Liver disease; Mechanism; Poria; Metabolic dysfunction-associated steatotic liver disease |
| Core Tip |
This study clarified the specific contribution of Poria (PR) as the “sovereign” drug in Fuling Zexie decoction (FZD) for metabolic dysfunction-associated steatotic liver disease. We confirmed that PR plays an irreplaceable role and its removal significantly weakened the therapeutic efficacy of FZD. The superior effects of FZD were attributed to diverse active components (six derived from PR), the specific regulation of five metabolic pathways (biotin, ascorbate/aldarate, alanine/aspartate/glutamate, inositol phosphate, and galactose metabolism), and 148 differential metabolites. Additionally, incorporating PR dregs enhanced antioxidant and anti-inflammatory activities, indicating that water-insoluble polysaccharides are key bioactive constituents. |
| Publish Date |
2026-07-24 07:03 |
| Citation |
Tao YX, Gong DH, Yang H, Wang PQ, Tang YM, Zhou QD, Wang YY, Zhang Y, Chen WD, Yu J, Yang XX. Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances. World J Hepatol 2026; 18(7): 121954
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i7/121954.htm |
| DOI |
https://doi.org/10.4254/wjh.121954 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
